Nivolumab tends to improve survival and response in HCC with PD-L1 expression ≥ 1%, but heterogeneity of PD-L1 expression and diversity of detection methods limit its utility (19, 34). The gene discussed is CD274; the disease is hepatocellular carcinoma.